Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorTishreen University

About this trial

This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects. The study will include patients presenting with congenital, traumatic, or post-surgical facial deformities requiring reconstructive intervention.

Eligible participants will undergo preoperative clinical assessment and radiological imaging to design customized implants using computer-aided design (CAD) and 3D printing technology. The implants will be fabricated from medical-grade titanium and surgically placed according to standardized maxillofacial reconstructive protocols.

Postoperative follow-up will assess functional outcomes, implant stability, complication rates, and aesthetic improvement over a defined observation period. Outcome evaluation will include clinical examination and patient-reported satisfaction measures.

The objective of this study is to determine whether patient-specific 3D-printed titanium implants provide reliable functional restoration and improved aesthetic outcomes in facial reconstruction compared to conventional reconstructive techniques.

Eligibility criteria

Qualifiers

Age 18 years or older.

Presence of facial bone defects resulting from cystic or tumoral osteolytic lesions.

Acquired or congenital facial deformities associated with bony defects or facial asymmetry.

Patients requiring patient-specific 3D-printed titanium implants for maxillofacial reconstruction.

Disqualifiers

Active pathological lesions at the time of enrollment.

Age below 18 years.

History of radiotherapy within 12 months prior to enrollment.

Chronic untreated vitamin D deficiency.

Trial design

Treatments tested in this trial

  • Patient-specific titanium implants for facial reconstruction

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators